Ketamine Lit Review & Bibliography
Further Selected Bibliography
Ko K, Knight G, Rucker JJ, Cleare AJ. Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic
Review. Front Psychiatry. 2022;13:917199. Published 2022 Jul 12. doi:10.3389/fpsyt.2022.917199
Lowe H, Toyang N, Steele B, et al. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety
Disorders. Molecules. 2022;27(8):2520. Published 2022 Apr 14. doi:10.3390/molecules27082520
Reiff CM, Richman EE, Nemeroff CB, et al. Psychedelics and Psychedelic-Assisted Psychotherapy. Am J Psychiatry.
2020;177(5):391-410. doi:10.1176/appi.ajp.2019.19010035
Ioannis Alex Malidelis, MD Andrew Hunt, MD Awais Aftab, MD Medication-Assisted Psychotherapy: The Past and Future of
Psychiatry January 12, 2024 Psychiatric Times Vol 41, Issue 1
Yehuda R, Lehrner A Psychedelic Therapy—A New Paradigm of Care for Mental Health. JAMA. 2023;330(9):813–814.
doi:10.1001/jama.2023.12900
Greenway KT, Garel N, Jerome L, Feduccia AA. Integrating psychotherapy and psychopharmacology: psychedelic-assisted
psychotherapy and other combined treatments. Expert Rev Clin Pharmacol. 2020;13(6):655-670.
doi:10.1080/17512433.2020.1772054
Marguilho M, Figueiredo I, Castro-Rodrigues P. A unified model of ketamine's dissociative and psychedelic properties. J
Psychopharmacol. 2023;37(1):14-32. doi:10.1177/02698811221140011
E. Khorramzadeh, AO, & Lotfy, The Use of Ketamine in Psychiatry,Psychosomatics,Volume 14, Issue 6,2973,Pages 344-346,
ISSN 0033-3182,https://doi.org/10.1016/S0033-3182(73)71306-2.
Wolfson, P, & Hartelius, G. The ketamine papers. Santa Cruz, CA: MAPS. 2016
Krupitsky EM, Grinenko AY. Ketamine psychedelic therapy (KPT): a review of the results of ten years of research. J
Psychoactive Drugs. 1997;29(2):165-183. doi:10.1080/02791072.1997.10400185)
Kolp, E, Friedman, H ., Krupitsky, E, et al Ketamine psychedelic psychotherapy: Focus on its pharmacology, phenomenology,
and clinical applications. International Journal of Transpersonal Studies, 33(2), 84–140.. International Journal of Transpersonal
Studies, 33 (2). http://dx.doi.org/10.24972/ijts.2014.33.2.84
Carhart-Harris, R, Roseman, E. Haijen, D et al 2018, July. Psychedelics and the essential importance of context. Journal of
Psychopharmacology 32 (7):725–31. Epub 2018 Feb 15. doi:10.1177/0269881118754710.
Walsh Z, Mollaahmetoglu OM, Rootman J, et al. Ketamine for the treatment of mental health and substance use disorders:
comprehensive systematic review. BJPsych Open, 8(1), e19. 10.1192/bjo.2021.1061.
Johnson & Johnson Press Release. Esketamine Receives Breakthrough Therapy Designation from U.S. Food and Drug
Administration for Major Depressive Disorder with Imminent Risk for Suicide. Available at: https://www.jnj.com/media-center/
press-releases/esketamine-recieves-breakthrough-therapy-designation-from-us-food-and-drug-administration-for-major-
depressive-disorder-with-imminent-risk-of-suicide. Accessed January 16, 2024.
Dore J, Turnipseed B, Dwyer S, et al. Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and
Outcomes in Three Large Practices Administering Ketamine with Psychotherapy. J Psychoactive Drugs. 2019;51(2):189-198.
doi:10.1080/02791072.2019.1587556
Meshkat S, Haikazian S, Di Vincenzo JD, et al. Oral ketamine for depression: An updated systematic review. World J Biol
Psychiatry. 2023;24(7):545-557. doi:10.1080/15622975.2023.2169349
Swainson, J, Klassen, LJ, Brennan, S., et al. Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction
Potential and Recommendations for Judicious Prescribing. CNS drugs, 36(3), 239–251. 2022.https://doi.org/10.1007/
s40263-022-00897-2
Kheirkhah F, Tayyebi G, Rabiee SM, et al Efficacy of different doses of ketamine as a bolus in major depressive disorder.
Caspian J Intern Med. 2018;9(3):220-227. doi:10.22088/cjim.9.3.220
Drozdz SJ, Goel A, McGarr MW, et al. Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature. J
Pain Res. 2022;15:1691-1706. Published 2022 Jun 15. doi:10.2147/JPR.S360733An Expert Informed Introduction to the Elements of Psychedelic-Assisted Therapy, Brainfutures, 2022.
Mian MN, Altman BR, Low F, Earleywine M. Development of the Protective Strategies for Psychedelics Scale: A novel
inventory to assess safety strategies in the context of psychedelics. J Psychopharmacol. Published online December 4, 2023.
doi:10.1177/02698811231214060
Butler M, Jelen L, Rucker J. Expectancy in placebo-controlled trials of psychedelics: if so, so what?. Psychopharmacology
(Berl). 2022;239(10):3047-3055. doi:10.1007/s00213-022-06221-6
Syed, OA, Tsang, B Managing expectations with psychedelic microdosing. npj Mental Health Res 2, 19 2023. https://doi.org/
10.1038/s44184-023-00044-9
Kaertner LS, Steinborn MB, Kettner H, et al. Positive expectations predict improved mental-health outcomes linked to
psychedelic microdosing. Sci Rep. 2021;11(1):1941. Published 2021 Jan 21. doi:10.1038/s41598-021-81446-7
Lii, TR, Smith, AE, Flohr, JR et al. Randomized trial of ketamine masked by surgical anesthesia in patients with depression.
Nat. Mental Health 1, 876–886 2023. https://doi.org/10.1038/s44220-023-00140-x
Earleywine, M , Altman, BR & De Leo, J Cognitive Behavioral Therapy, Ketamine, and Combination Treatment for
Depression: Impressions of Credibility in Participants with Self-Reported Depressive Symptoms, Journal of Psychoactive Drugs,
54:1, 70-80, 2022 DOI: 10.1080/02791072.2021.1912863
Murphy R, Kettner H, Zeifman R, et al. Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy
for Depression. Front Pharmacol. 2022;12:788155. Published 2022 Mar 31. doi:10.3389/fphar.2021.788155
Zhao S, Sampson S, Xia J, Jayaram MB. Psychoeducation (brief) for people with serious mental illness. Cochrane Database of
Systematic Reviews 2015, Issue 4. Art. No.: CD010823. DOI: 10.1002/14651858.CD010823.pub2. Accessed 16 January 2024.
Barrett FS, Robbins H, Smooke D, Bet al. Qualitative and Quantitative Features of Music Reported to Support Peak Mystical
Experiences during Psychedelic Therapy Sessions. Front Psychol. 2017;8:1238. Published 2017 Jul 25. doi:10.3389/
fpsyg.2017.01238
Leary, T, Mettzner, R, & Alpert R, The psychedelic experience; a manual based on the Tibetan book of the dead New York
University Books; 1964.
Hartogsohn I. Constructing drug effects: A history of set and setting. Drug Science, Policy and Law. 2017;3.
doi:10.1177/2050324516683325
Hassan K, Struthers WM, Sankarabhotla A et al. Safety, effectiveness and tolerability of sublingual ketamine in depression and
anxiety: A retrospective study of off-label, at-home use. Front. Psychiatry 13:992624. 2022 doi: 10.3389/fpsyt.2022.992624
Hull TD, Malgaroli M, Gazzaley A, et al. At-home, sublingual ketamine telehealth is a safe and effective treatment for
moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial. Journal of Affective
Disorders. 2022 Oct 1;314:59-67. https://doi.org/10.1016/j.jad.2022.07.004
Swainson, J, Klassen, LJ, Brennan, S, . Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential
and Recommendations for Judicious Prescribing. CNS drugs, 36(3), 239–251. 2022. https://doi.org/10.1007/s40263-022-00897-2
Benini F, Congedi S, Giacomelli L, et al, Refractory symptoms in paediatric palliative care: can ketamine help?. Drugs
Context. 2021;10:2021-2-5. Published 2021 May 19. doi:10.7573/dic.2021-2-5
Goldman N, Frankenthaler M, Klepacz L. The Efficacy of Ketamine in the Palliative Care Setting: A Comprehensive Review
of the Literature. J Palliat Med. 2019;22(9):1154-1161. doi:10.1089/jpm.2018.0627
Soto E, Stewart DR, Mannes AJ, et al. Oral ketamine in the palliative care setting: a review of the literature and case report of a
patient with neurofibromatosis type 1 and glomus tumor-associated complex regional pain syndrome. Am J Hosp Palliat Care.
2012;29(4):308-317. doi:10.1177/1049909111416345
Mediano PAM, Rosas FE, Timmermann C, et al. Effects of External Stimulation on Psychedelic State Neurodynamics. ACS
Chem Neurosci. Published online January 12, 2024. doi:10.1021/acschemneuro.3c00289
Kolp, E, Friedman, H ., Krupitsky, E, et al Ketamine psychedelic psychotherapy: Focus on its pharmacology, phenomenology,
and clinical applications. International Journal of Transpersonal Studies, 33(2), 84–140.. International Journal of Transpersonal
Studies, 33 (2). http://dx.doi.org/10.24972/ijts.2014.33.2.84
Swainson J, Khullar A. Sublingual ketamine: an option for increasing accessibility of ketamine treatments for depression? J
Clin Psychiatry 2020; 81(1): 19lr13146.
Jansen, KLR The Ketamine Model of the Near-Death Experience: A Central Role for the N-Methyl-D-Aspartate Receptor.
Journal of Near-Death Studies 16, 5–26 1997. https://doi.org/10.1023/A:1025055109480
Niciu MJ, Shovestul BJ, Jaso BA, et al. Features of dissociation differentially predict antidepressant response to ketamine in
treatment-resistant depression. J Affect Disord. 2018;232:310-315. doi:10.1016/j.jad.2018.02.049
Luckenbaugh DA, Niciu MJ, Ionescu DF, et al. Do the dissociative side effects of ketamine mediate its antidepressant effects?.
J Affect Disord. 2014;159:56-61. doi:10.1016/j.jad.2014.02.017
Ko K, Knight G, Rucker JJ, Cleare AJ. Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic
Review. Front Psychiatry. 2022;13:917199. Published 2022 Jul 12. doi:10.3389/fpsyt.2022.917199
Hack, L.M., Zhang, X., Heifets, B.D. et al. Ketamine’s acute effects on negative brain states are mediated through distinct
altered states of consciousness in humans. Nat Commun 14, 6631 2023. https://doi.org/10.1038/s41467-023-42141-5
Romand R, Ehret G. Neuro-functional modeling of near-death experiences in contexts of altered states of consciousness. Front
Psychol. 2023;13:846159. Published 2023 Jan 18. doi:10.3389/fpsyg.2022.846159
Timmermann C, Roseman L, Williams L, et al DMT Models the Near-Death Experience. Front. Psychol. 9:1424. 2018 doi:
10.3389/fpsyg.2018.01424
Mathai DS, Mora V, Garcia-Romeu A. Toward Synergies of Ketamine and Psychotherapy. Front Psychol. 2022;13:868103.
Published 2022 Mar 25. doi:10.3389/fpsyg.2022.868103
Kolp, E., Friedman, H. L., Krupitsky, E., et al (2014). Ketamine psychedelic psychotherapy: Focus on its pharmacology,
phenomenology, and clinical applications. International Journal of Transpersonal Studies, 33(2), 84–140.. International Journal of
Transpersonal Studies, 33 (2). http://dx.doi.org/10.24972/ijts.2014.33.2.84
Pahnke, WN, & Richards, WA. Implications of LSD and Experimental Mysticism. Journal of Religion and Health, 5(3), 175–
208.1996 .http://www.jstor.org/stable/27504799
Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R. Psilocybin occasioned mystical-type experiences:
immediate and persisting dose-related effects. Psychopharmacology (Berl). 2011;218(4):649-665. doi:10.1007/
s00213-011-2358-5
Roseman, L., Nutt, D.J., & Carhart-Harris, R.L. (2018). Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy
of Psilocybin for Treatment-Resistant Depression. Frontiers in Pharmacology, 8.
Dai R, Larkin TE, Huang Z, et al. Classical and non-classical psychedelic drugs induce common network changes in human
cortex. Neuroimage. 2023;273:120097. doi:10.1016/j.neuroimage.2023.120097
Alexander, L, Hawkins, PCT, Evans, JW et al. Preliminary evidence that ketamine alters anterior cingulate resting-state
functional connectivity in depressed individuals. Transl Psychiatry 13, 371 (2023). https://doi.org/10.1038/s41398-023-02674-1
Stoliker D., Novelli L., et al, Neural Mechanisms of Resting-State Networks and the Amygdala underlying the Cognitive and
Emotional Effects of Psilocybin, Biological Psychiatry (2024), doi: https://doi.org/10.1016/ j.biopsych.2024.01.002.
Scheidegger M, Henning A, Walter M, et al. Ketamine administration reduces amygdalo-hippocampal reactivity to emotional
stimulation. Hum Brain Mapp. 2016;37(5):1941-1952. doi:10.1002/hbm.23148
Bathje GJ, Majeski E and Kudowor M Psychedelic integration: An analysis of the concept and its practice. Front. Psychol.
13:824077. 2022. doi: 10.3389/fpsyg.2022.824077
Aixalà, M. Psychedelic integration: Psychotherapy for non-ordinary states of consciousness. Synergetic Press. 2022
Frymann T, Whitney S, Yaden DB and Lipson J (2022) The Psychedelic Integration Scales: Tools for Measuring Psychedelic
Integration Behaviors and Experiences. Front. Psychol. 13:863247. 2022. doi: 10.3389/fpsyg.2022.863247
Dunlop BW, Rajendra JK, Craighead WE, et al. Functional connectivity of the subcallosal cingulate cortex and differential
outcomes to treatment with cognitive-behavioral therapy or antidepressant medication for major depressive disorder. Am J
Psychiatry. 2017;174:533–45.
Kumar V, Sattar Y, Bseiso A, et al. The Effectiveness of Internet-Based Cognitive Behavioral Therapy in Treatment of
Psychiatric Disorders. Cureus. 2017;9(8):e1626. Published 2017 Aug 29. doi:10.7759/cureus.1626
Yaden DB, Earp D, Graziosi M, et al. Psychedelics and Psychotherapy: Cognitive-Behavioral Approaches as Default. Front
Psychol. 2022;13:873279. Published 2022 May 23. doi:10.3389/fpsyg.2022.873279
Wilkinson ST, Rhee TG, Joormann J, et al. Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in
Treatment-Resistant Depression: A Randomized Clinical Trial. Psychother Psychosom. 2021;90(5):318-327.
doi:10.1159/000517074
Davis AK, Barrett FS, Griffiths RR. Psychological flexibility mediates the relations between acute psychedelic effects and
subjective decreases in depression and anxiety. J Contextual Behav Sci. 2020;15:39-45. doi:10.1016/j.jcbs.2019.11.004
Wolff M, Evens R, Mertens LJ, et al Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy
Promotes Acceptance. Front. Psychiatry 11:5. 2020 doi: 10.3389/fpsyt.2020.00005
Ellis, A The road to tolerance: The philosophy of rational emotive behavior therapy. Prometheus Books. 2004
Rosner, R, Albert Ellis' rational-emotive behavior therapy. Adolescent Psychiatry, 1(1), 82–87. 2011 https://doi.org/
10.2174/2210676611101010082
SmartRecovery.org Accessed January 16, 2024.https://smartrecovery.org
Newby, J, Mason, E,Kladnistki , Net al. Integrating internet CBT into clinical practice: a practical guide for clinicians, Clinical
Psychologist, 25:2, 164-178,2021. DOI: 10.1080/13284207.2020.1843968
González D, Aixalà MB, Neimeyer RA, Cantillo J, Nicolson D, Farré M. Restorative Retelling for Processing Psychedelic
Experiences: Rationale and Case Study of Complicated Grief. Front Psychol. 2022;13:832879. Published 2022 May 3.
doi:10.3389/fpsyg.2022.832879
William E. Rosa, Zachary Sager, Megan Miller, et al.Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-
Assisted Therapy in the Context of Serious Illness.Journal of Palliative Medicine.Aug 2022.1273-1281.http://doi.org/10.1089/
jpm.2022.0036
An Expert Informed Introduction to the Elements of Psychedelic-Assisted Therapy, Brainfutures, 2022.
Phelps, J Developing Guidelines and Competencies for the Training of Psychedelic Therapists Journal of Humanistic
Psychology, 2017, 1–38 DOI: 10.1177/0022167817711304
Delli Colli, C., Chiarotti, F., Campolongo, P. et al. Towards a network-based operationalization of plasticity for predicting the
transition from depression to mental health. Nat. Mental Health (2024). https://doi.org/10.1038/s44220-023-00192-z
Hyde, S Ketamine and depression. Xlibris. 2015
Wolfson, P, & Hartelius, G editors.. The Ketamine Papers. MAPS. 2016
Breitbart W. Existential isolation. Palliat Support Care. 2017;15(4):403-404. doi:10.1017/S1478951517000621